Company Overview
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertakes the research activities for the POP1 Program and the University of Granada to develop a synthetic recombinant version of PRP. Propanc Biopharma, Inc. was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. The company was incorporated in 2007 and is based in Camberwell, Australia.
Why Investors Should Care
Return on capital employed stands at 41.3%.
Carries low leverage with a debt-to-equity ratio of 0.05.
Generates positive free cash flow, funding growth and shareholder returns internally.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -99.48% |
| 6 Months: | -76.05% |
| 3 Months: | -24.82% |
| 1 Month: | -14.17% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)44.77 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Healthy ROCE of 41.3%.
- Generates positive free cash flow.
CONS
- Trading 99.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PPCB Propanc Biopharma, Inc. PHARMA | 1.03 | 0.00 | $2.35M | 0.00% | 41.29% | -126.98% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2013 | Sep 2013 | Dec 2013 | Mar 2014 | Sep 2014 | Dec 2014 | Mar 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 213.38K | 53.13M | 4.67M | 3.65M | 6.40M |
| Operating Income | -229.37K | -308.57K | -225.45K | -104.31K | -238.14K | -249.44K | -516.57K | -1.01M | -1.14M | -1.29M | -1.17M | -1.91M | -1.55M | -1.20M | -1.44M | -807.13K | -448.87K | -757.82K | -571.73K | -909.42K | -1.38M | -607.17K | -383.16K | -274.09K | -427.95K | -486.03K | -403.47K | -502.18K | -572.83K | -608.00K | -386.21K | -417.22K | -438.06K | -420.87K | -290.79K | -213.38K | -53.13M | -4.67M | -3.65M | -6.40M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -306.91K | -53.96M | -4.53M | -3.03M | -6.32M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 118.94K | 104.04K | 305.65K | 58.95K | 38.27K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -430.18K | -54.07M | -4.84M | -3.09M | -6.36M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Net Income | -337.67K | -571.51K | 26.40K | -66.86K | -783.30K | -345.48K | -454.25K | -838.89K | -3.56M | -2.15M | -1.10M | -3.76M | -1.37M | -1.92M | -2.20M | -1.49M | -2.12M | -1.45M | -581.86K | -1.49M | -1.87M | -2.59M | -425.55K | -403.64K | -417.74K | -490.66K | -799.98K | -462.69K | -617.29K | -485.42K | -809.81K | -350.87K | -584.38K | -526.70K | -354.31K | -430.18K | -54.07M | -4.84M | -3.09M | -6.36M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.13 | -0.53 | -0.42 | -0.04 | -1,559.55 | -545.79 | -35.97 | -32.23 | -12.50 | -0.39 | -0.30 | -7.00 |
| R&D Expense | - | 0 | 0 | 0 | 3.88K | 2.44K | 9.47K | 153.47K | 142.80K | 510.30K | 161.20K | 167.20K | 386.49K | 563.74K | 1.03M | 75.14K | 56.19K | 94.78K | 52.66K | 65.37K | 37 | 57.48K | 50.85K | 50.16K | 44.89K | 46.55K | 50.75K | 50.40K | 101.33K | 74.88K | 66.02K | 16.24K | 114.02K | 65.45K | 61.71K | 54.39K | 54.10K | 60.20K | 19.96K | 169.66K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jun 2009 | Jun 2010 | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.99M | 1.78M | 1.54M | - |
| Operating Income | - | - | -2.24M | -11.59M | -1.36M | -761.22K | -1.71M | -6.90M | -5.74M | -3.96M | -2.61M | -3.49M | -1.81M | -1.99M | -1.78M | -1.54M | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.14M | -2.23M | -1.26M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 568.80K | 532.82K | 665.84K | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.71M | -2.79M | -1.95M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | -54.98K | -129.84K | -129.13K | - |
| Net Income | -443.85K | -842.49K | -2.15M | -11.43M | -1.44M | -829.56K | -3.41M | -9.41M | -7.87M | -7.04M | -5.76M | -4.74M | -2.03M | -2.66M | -2.66M | -1.82M | - |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | -1,119,475.67 | -781,709.75 | -1,420.53 | -14.85 |
| R&D Expense | - | - | 385.78K | 5.28K | 12.34K | 8.17K | 134.32K | 1.45M | 971.77K | 1.83M | 260.33K | 179.99K | 230.96K | 256.05K | 247.92K | 248.10K | 223.72K |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jun 2008 | Jun 2009 | Jun 2010 | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | 10.81M | 46.27K | 1.75K | 113.75K | 627.07K | 379.14K | 95.07K | 71.39K | 101.65K | 98.52K | 13.10K | 81.65K | 60.33K | 72.36K | - |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 15.03K | 19.04K | 25.44K | - |
| Cash & Equivalents | - | - | - | 132 | 179 | 0 | 87.80K | - | - | - | - | - | 67.01K | 2.25K | 4.07K | 10.05K | 21.09K | - |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.34K | 2.87K | 2.95K | - |
| Total Liabilities | - | - | - | 306.85K | 584.19K | - | - | - | - | - | - | 4.40M | 3.74M | 3.08M | 3.11M | 3.18M | 3.85M | - |
| Current Liabilities | - | - | - | 306.85K | 584.19K | 794.22K | 1.52M | 3.68M | 2.94M | 5.54M | 6.82M | 4.40M | 3.74M | 3.08M | 3.06M | 3.16M | 3.79M | - |
| Long Term Debt | - | - | - | - | - | - | - | - | 1.20M | 3.48M | 4.70M | 1.66M | 1.56M | 624.58K | - | - | 58.64K | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.04M | 545.92K | 948.27K | - |
| Total Equity | 85.13K | -409.39K | -186.90K | 10.51M | -537.92K | -792.48K | -1.41M | -3.05M | -2.57M | -5.44M | -6.75M | -4.30M | -3.64M | -3.07M | -3.02M | -3.12M | -3.78M | - |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3 | 4 | 319 | 464.47K |
Cash Flows (Annual)
Figures in USD.
| Metric | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.40M | -170.28K | -128.65K | 226.44K | - | - | -2.05M | -2.18M | -2.06M | -1.85M | -1.15M | -1.44M | -1.11M | -935.12K | - |
| Investing Cash Flow | -29.23K | - | - | 0 | -5.58K | - | - | - | -2.87K | - | - | - | - | - | - |
| Financing Cash Flow | 1.42M | 170.33K | 128.47K | - | - | - | 2.10M | 2.40M | 2.12M | 1.89M | 1.06M | 1.49M | 1.11M | 941.89K | - |
| Capital Expenditure | -3.51K | - | - | -0 | -3.90K | -9.88K | - | - | -2.87K | - | - | - | - | - | - |
| Free Cash Flow | -1.40M | - | - | 226.44K | - | - | - | - | -2.06M | - | - | -1.44M | -1.11M | -935.12K | - |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | 54.48K | 8.47K | 6.78K | - |
Ratios (Annual)
Figures in %.
| Metric | Jun 2009 | Jun 2010 | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| ROE % | 108.4% | 450.8% | -20.5% | 2,125.7% | 182.0% | 58.9% | 111.8% | 366.8% | 144.6% | 104.3% | 133.9% | 130.2% | 66.0% | 87.9% | 85.4% | 48.2% | - |
| ROCE % | - | - | -21.3% | 2,154.6% | 171.9% | 54.1% | 55.9% | 268.9% | 105.5% | 58.6% | 60.8% | 96.0% | 59.1% | 66.8% | 57.3% | 41.3% | - |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Jane Street Group, LLC | 0.73% | 25.55K | $15.59K |
| 2 | Citadel Advisors Llc | 0.35% | 12.09K | $7.37K |
| 3 | HRT Financial LP | 0.29% | 10.24K | $6.25K |
| 4 | Caitong International Asset Management Co., Ltd | - | 2 | $1 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PPCB
Propanc’s pancreatic cancer candidate extends animal survival more than 2.5-fold - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxOR3FLdGN2dEt2ZTRYUVVEQTZpNDIxTzJ5YU82bWtmRFd3akZDRzNucHl5NExqS0MtOW0yd21QTnhWcnhrcTJEc3AwbEFtamJBR0VyZG4tbkVWU0ZpN3R4TmU4SjY2QXJ3aW9ENWZFRncxRUlXRURkWDM0SGtseEVKZ0VGdG55Zl9Ha0RFOU…
PPCB Stock Surges Over 200% Just Days After Implementing Reverse Share Split – What’s Driving Today’s Smashing Rally? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxQRURqTlBGSnMzUEZ3SFV0d3hPOURZcmdibXpIN2cxeHRTWUpjY0FhVFVmb3d6dEh1cFptbF9LcHg3bjhVUFVKWjVxa3ItWHdxYTh3NjRrcDRyc1plTXJPeHAybl9MMkh1dWhYRTgwNFBJVXNVSHpVNW1RclJhUWRxLVI1TVJPc0FzbXBRVF…
Propanc Biopharma Surges After New Pancreatic Cancer Data - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxQNjRaTnBpem5lcExaS09rQXIwbVNLZ3NBRlNWVG5DN2RhMkswTnl4TXVqUlI2VVdWbkpZZWVSNWlnTEdGNkJpWmtEQnVNSUpWdnJCbEUzUlp3Q1hYR19lRzVNLTlFVk9DcGNheUtVY2F0SGxjQk5ScDNpM2laYWlLcGltazZJbTN6M1Y3aT…
PPCB - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE5JVW54QU5uS3NzQ1BGenF4bGJYWHJ4ZUMybEpIS2l2bWdJNktuUko3cmtRdTk1VkZJWDdjQTdJYS1WVm1xNUE?oc=5" target="_blank">PPCB</a> <font color="#6f6f6f">Finviz</font>…
PPCB Should I Buy - Intellectia AI
<a href="https://news.google.com/rss/articles/CBMiXkFVX3lxTE9ybkxqNGVQZjZQQmgyb0Y0X3VwR0NzbFRMQUUtTnVTdGpuQTFoQkU0U2ljMlM5NlJVdUhhMko0a1dNWGZvUUI5Z0xhYUd0bFpfdzA1dVNrRU1jYjFURGc?oc=5" target="_blank">PPCB Should I Buy</a> <font c…
PPCB Stock Explodes As PRP Trial Plans Heat Up - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMif0FVX3lxTE9hMmJOMk5CN3BVeVB3amxDd1g0bUZhMm4yZGV4RDI0MUpNRDZybThUV202cmRJRWJiSmFxS1FrdE5jV0ZLT0luQnluY0RRVGFKcXllZ2Z1aDdmNHZRMHRVUWRueThUMC02NmQtTUV4T0pMV1oya0luSFJDYjZoRms?oc=5" target="_bla…
PPCB — Frequently Asked Questions
What is the current share price of Propanc Biopharma, Inc. (PPCB)?
As of 2026-09-19 21:16 PDT, Propanc Biopharma, Inc. (PPCB) trades at $1.03 on NasdaqCM. Its 52-week range is $0.99 to $260.00.
What is the market capitalisation of PPCB?
Propanc Biopharma, Inc. (PPCB) has a market capitalisation of $2.35M on NasdaqCM.
What is the return on equity (ROE) of PPCB?
PPCB has a return on equity (ROE) of -126.98%. Its return on capital employed (ROCE) is 41.29%.
Is PPCB a good stock to buy?
This page provides a data-driven analysis of Propanc Biopharma, Inc. (PPCB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.